United Therapeutics
Biotechnology company developing photopolymer-based 3D bioprinting systems (Print to Perfusion) for manufacturing vascularized, transplantable human organs with patient-derived stem cells, plus five FDA-approved drugs for pulmonary hypertension and oncology
- CEO / Founder
- Martine Rothblatt
- Team Size
- 501-1000
- Stage
- Active
- Total Funding
- $12M
- Latest Round
- IPO - $56.4M - June 1999
- Key Investors
- Public Investors, Private Investors, Deutsche Banc Alex. Brown (IPO underwriter)
Technology & Products
Key Products
Remodulin (treprostinil) Injection - PAH, FDA approved 2002/2004; Tyvaso (treprostinil) Inhalation Solution - PAH, FDA approved 2009; Tyvaso DPI (treprostinil) Inhalation Powder - PAH/PH-ILD, FDA approved; Orenitram (treprostinil) Extended-Release Tablets - PAH, FDA approved 2013; Adcirca (tadalafil) Tablets - PAH, FDA approved 2009; Unituxin (dinutuximab) Injection - Neuroblastoma/Oncology, FDA approved 2015; Print to Perfusion - Advanced photopolymer-based bioprinting technology for organ scaffolds
Technological Advantage
Proprietary photopolymer bioprinting process in partnership with 3D Systems; patent-protected bioprinting methodology; unique approach combining 3D printing with patient-derived stem cell cellularization; enables manufacturing of complex, vascularized organs previously impossible; positioned to disrupt $40B+ global organ transplant market by eliminating donor organ scarcity
Differentiation
Value Proposition
Print to Perfusion bioprinting technology enables full-size, micron-level organ scaffolds printable in ~3 weeks; cellularized with patient's own stem cells eliminates need for immunosuppression and organ rejection risk; unlimited scalable supply vs. donor organ scarcity
How They Differentiate
Unique Print to Perfusion photopolymer-based bioprinting vs. inkjet/extrusion competitors; demonstrated vascularized organ capability (44 trillion voxel lungs); patient-derived stem cell cellularization eliminates immunosuppression requirement; 3-week production timeline for full-size organs; strategic partnership with 3D Systems for manufacturing expertise; $2.5B+ annual revenue base funds R&D advantage
Market & Competition
Target Customers
Organ transplant patients; pulmonary hypertension patients; neuroblastoma patients
Industry Verticals
Pharmaceutical/Biotechnology; Medical Devices; Regenerative Medicine; Organ Transplantation; Additive Manufacturing
Competitors
Organovo; Aspect Biosystems
Growth & Milestones
Growth Metrics
5 FDA-approved drugs generating $2.5B+ annual revenue; 501-1,000 employees; $15B+ market capitalization (2024-2025); bioprinting lung scaffolds with animal model gas exchange capability; 3D-printed organ scaffold production time: 3 weeks
Major Milestones
Founded 1996 by Martine Rothblatt (motivated by daughter's PAH diagnosis); IPO June 17, 1999 (NASDAQ: UTHR, priced at $12/share); Remodulin FDA approval 2002 (subcutaneous) and 2004 (IV); Tyvaso FDA approval 2009; Orenitram FDA approval 2013, commercial launch 2014; Unituxin FDA approval 2015 (oncology); 3D Systems bioprinting partnership announced 2017; 3D printed human lung scaffold revealed June 2022 (Print to Perfusion technology); Demonstrated gas exchange in animal models (3D Systems partnership, 2023-2024); Founder/CEO Rothblatt insider buying spree driving >$15B market cap (2024-2025)
Notable Customers
Pulmonary hypertension patients (global market, 3M+ diagnosed); Organ transplant recipients (global shortage: 10,000+ annual deaths on waitlists); Healthcare systems (EVLP lung perfusion service providers)